Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03049618
Recruitment Status : Active, not recruiting
First Posted : February 10, 2017
Last Update Posted : November 18, 2021
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Southern California

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 10, 2023
Estimated Study Completion Date : March 10, 2024